| Product Code: ETC6068776 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Andorra Cerebral Vasospasm Market Overview |
3.1 Andorra Country Macro Economic Indicators |
3.2 Andorra Cerebral Vasospasm Market Revenues & Volume, 2021 & 2031F |
3.3 Andorra Cerebral Vasospasm Market - Industry Life Cycle |
3.4 Andorra Cerebral Vasospasm Market - Porter's Five Forces |
3.5 Andorra Cerebral Vasospasm Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.6 Andorra Cerebral Vasospasm Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.7 Andorra Cerebral Vasospasm Market Revenues & Volume Share, By End-User, 2021 & 2031F |
4 Andorra Cerebral Vasospasm Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Growing awareness among healthcare professionals about the diagnosis and treatment of cerebral vasospasm |
4.2.2 Advancements in medical technology for better detection and management of cerebral vasospasm |
4.2.3 Increasing prevalence of risk factors such as hypertension and smoking leading to a rise in cerebral vasospasm cases |
4.3 Market Restraints |
4.3.1 High treatment costs associated with managing cerebral vasospasm |
4.3.2 Limited availability of specialized healthcare facilities for the treatment of cerebral vasospasm |
5 Andorra Cerebral Vasospasm Market Trends |
6 Andorra Cerebral Vasospasm Market, By Types |
6.1 Andorra Cerebral Vasospasm Market, By Diagnosis |
6.1.1 Overview and Analysis |
6.1.2 Andorra Cerebral Vasospasm Market Revenues & Volume, By Diagnosis, 2021- 2031F |
6.1.3 Andorra Cerebral Vasospasm Market Revenues & Volume, By CT Scan, 2021- 2031F |
6.1.4 Andorra Cerebral Vasospasm Market Revenues & Volume, By Computed Tomography Angiography (CTA), 2021- 2031F |
6.1.5 Andorra Cerebral Vasospasm Market Revenues & Volume, By Digital Subtraction Angiography (DSA), 2021- 2031F |
6.1.6 Andorra Cerebral Vasospasm Market Revenues & Volume, By Magnetic Resonance Angiography (MRA), 2021- 2031F |
6.1.7 Andorra Cerebral Vasospasm Market Revenues & Volume, By Transcranial Doppler (TCD), 2021- 2031F |
6.2 Andorra Cerebral Vasospasm Market, By Treatment |
6.2.1 Overview and Analysis |
6.2.2 Andorra Cerebral Vasospasm Market Revenues & Volume, By Nimodipine, 2021- 2031F |
6.2.3 Andorra Cerebral Vasospasm Market Revenues & Volume, By Triple-H Therapy, 2021- 2031F |
6.2.4 Andorra Cerebral Vasospasm Market Revenues & Volume, By Balloon Angioplasty, 2021- 2031F |
6.2.5 Andorra Cerebral Vasospasm Market Revenues & Volume, By Vasopressors, 2021- 2031F |
6.2.6 Andorra Cerebral Vasospasm Market Revenues & Volume, By Inotropes, 2021- 2031F |
6.2.7 Andorra Cerebral Vasospasm Market Revenues & Volume, By Thrombolytic Agents, 2021- 2031F |
6.3 Andorra Cerebral Vasospasm Market, By End-User |
6.3.1 Overview and Analysis |
6.3.2 Andorra Cerebral Vasospasm Market Revenues & Volume, By Hospitals and Clinics, 2021- 2031F |
6.3.3 Andorra Cerebral Vasospasm Market Revenues & Volume, By Ambulatory Surgical Centers, 2021- 2031F |
6.3.4 Andorra Cerebral Vasospasm Market Revenues & Volume, By Trauma Centers, 2021- 2031F |
6.3.5 Andorra Cerebral Vasospasm Market Revenues & Volume, By Emergency Departments, 2021- 2031F |
6.3.6 Andorra Cerebral Vasospasm Market Revenues & Volume, By Others, 2021- 2031F |
7 Andorra Cerebral Vasospasm Market Import-Export Trade Statistics |
7.1 Andorra Cerebral Vasospasm Market Export to Major Countries |
7.2 Andorra Cerebral Vasospasm Market Imports from Major Countries |
8 Andorra Cerebral Vasospasm Market Key Performance Indicators |
8.1 Average length of hospital stay for cerebral vasospasm patients |
8.2 Number of clinical trials focusing on new treatment options for cerebral vasospasm |
8.3 Rate of adoption of minimally invasive procedures for cerebral vasospasm treatment |
9 Andorra Cerebral Vasospasm Market - Opportunity Assessment |
9.1 Andorra Cerebral Vasospasm Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.2 Andorra Cerebral Vasospasm Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.3 Andorra Cerebral Vasospasm Market Opportunity Assessment, By End-User, 2021 & 2031F |
10 Andorra Cerebral Vasospasm Market - Competitive Landscape |
10.1 Andorra Cerebral Vasospasm Market Revenue Share, By Companies, 2024 |
10.2 Andorra Cerebral Vasospasm Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |